Table 1.

Patient characteristics

CharacteristicValue
Mean age50 years (range, 38-64)
Menstrual status before treatment
    Premenopausal6 patients
    Postmenopausal4 patients
Neoadjuvant treatment
    Chemoradiotherapy3 patients
    Epirubicin and docetaxel2 patients
    AC + T2 patients
    FEC + D1 patient
    Sunitinib/trastuzumab→docetaxel/trastuzumab/pamidronate1 patient
    Docetaxel/carboplatinum/trastuzumab1 patient
Mean maximum tumor size7.7 ± 2.4 cm (range, 5-11.2)
Tumor histology
    Lobular carcinoma2 patients
    Ductal carcinoma8 patients
Hormone receptor (estrogen or progesterone receptor)
    Positive7 patients
    Negative3 patients
Mean body mass index25.2 ± 7.0
Her-2-neu
    Positive4 patients
    Negative6 patients
Triple negative (estrogen, progesterone, and Her-2-neu)2 patients
Grade
    10 patients
    210 patients
    30 patients

Abbreviations: AC, Adriamycin/cyclophosphamide; T, trastuzumab; FEC, 5-fluourouracil/epirubicin/cyclophosphamide; D, docetaxel.